Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.88 |
| ▸ | GSK3B | P49841 | 2/20 | 0.88 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.88 |
| ▸ | UBE2N | P61088 | 1/20 | 0.88 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.79 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.79 |
| ▸ | DPP4 | P27487 | 1/20 | 0.75 |
| ▸ | KDM1A | O60341 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.65 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.65 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.65 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | XDH | P47989 | 2/20 | 0.64 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.51 |
| ▸ | P4HB | P07237 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20437861 | 1.00 | PKM (1.00) | PKMPTPN1GSK3BCYP19A1UBE2N | |
| SCHEMBL29366330 | 1.00 | PKM (1.00) | PKMPTPN1GSK3BCYP19A1UBE2N | |
| Naringin SCHEMBL20386954 | 0.94 | PTPN1 (1.00) | PKMPTPN1GSK3BCYP19A1UBE2N | |
| Naringin SCHEMBL1201445 | 0.94 | PTPN1 (1.00) | PKMPTPN1GSK3BCYP19A1UBE2N | |
| Naringin SCHEMBL13237107 | 0.94 | PTPN1 (1.00) | PKMPTPN1GSK3BCYP19A1UBE2N | |
| Naringin SCHEMBL23431 | 0.94 | PTPN1 (1.00) | PKMPTPN1GSK3BCYP19A1UBE2N | |
| Naringin SCHEMBL16592383 | 0.94 | PTPN1 (1.00) | PKMPTPN1GSK3BCYP19A1UBE2N | |
| Naringin SCHEMBL2614060 | 0.94 | PTPN1 (1.00) | PKMPTPN1GSK3BCYP19A1UBE2N | |
| Naringin SCHEMBL20383126 | 0.94 | PTPN1 (1.00) | PKMPTPN1GSK3BCYP19A1UBE2N | |
| Naringin SCHEMBL14114613 | 0.94 | PTPN1 (1.00) | PKMPTPN1GSK3BCYP19A1UBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4617293-A | Flavonoid phosphate salts of aminoglycoside antibiotics | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1986-10-14 | — | — | US | claimed |
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RES CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| WO-2021144447-A1 | PLANT EXTRACT COMPOSITION FOR THE TREATMENT OF CARDIOVASCULAR AND METABOLIC DISEASES | MEDA Pharma S.p.A. (IT) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021144446-A1 | PLANT EXTRACT COMPOSITION FOR THE TREATMENT OF LIVER STEATOSIS | MEDA Pharma S.p.A. (IT) | 2021-07-22 | — | — | WO | disclosed |
| CN-107929301-A | Application of the neoeriocitrin in protein expression conditioning agent is prepared | 黑龙江葆纳生物科技有限责任公司 | 2018-04-20 | — | — | CN | disclosed |
| EP-1286706-A2 | GAMMA IRRADIATION OF PROTEIN-BASED PHARMACEUTICAL PRODUCTS | The American National Red Cross (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001087357-A2 | GAMMA IRRADIATION OF PROTEIN-BASED PHARMACEUTICAL PRODUCTS | THE AMERICAN NATIONAL RED CROSS (US) | 2001-11-22 | — | — | WO | disclosed |
| US-4617293-A | Flavonoid phosphate salts of aminoglycoside antibiotics | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1986-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339399-A1 | SUPRAMOLECULAR SELF-ASSEMBLY SYSTEM | S100A8, TP53, AQP1 | PKM 3085/4885PTPN1 2775/4885GSK3B 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.